TAR-200

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Bladder CancerUrothelial CarcinomaUrinary Bladder NeoplasmsNon-Muscle Invasive Bladder Neoplasms

378 competitors in Bladder Cancer

#DrugCompanyPhaseTrials

1

Gemzar

Johnson & Johnson

Phase 3

572

Keytruda

Merck & Co.

Phase 3

313

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

614

Padcev

Pfizer

Phase 3

135

Trexall

Alnylam Pharmaceuticals

Phase 3

136

Javlor

Bristol-Myers Squibb

Phase 3

57

Paraplatin

AAvyxa

Phase 3

98

Ornidyl

UUSWM, LLC (dba US WorldMeds)

Phase 3

19

Bacillus Calmette-Guerin

AstraZeneca

Phase 3

710

Bempegaldesleukin

NNektar Therapeutics

Phase 3

1Show 30 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Bladder Cancer2 trials

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Active, not recruiting·Johnson & Johnson·Phase 2·NCT04640623·220 enrolled

A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer

Active, not recruiting·Johnson & Johnson·Phase 3·NCT05714202·1,135 enrolled

Non-Muscle Invasive Bladder Neoplasms2 trials

17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)

Active, not recruiting·Johnson & Johnson·Phase 3·NCT06211764·272 enrolled

Pre-Approval Access US Intermediate Size Expanded Access Protocol for TAR-200 Treating Physician Use

Approved for marketing·Johnson & Johnson··NCT06877676

Urinary Bladder Neoplasms2 trials

A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy

Active, not recruiting·Johnson & Johnson·Phase 3·NCT04658862·518 enrolled

A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

Completed·Johnson & Johnson·Phase 2·NCT04919512·163 enrolled

Urothelial Carcinoma1 trial

A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

Completed·Johnson & Johnson·Phase 1·NCT03404791·35 enrolled

Details

Drug Info

Related News